Treatment response with intensive and nonintensive blast-reduction therapies
| OUTCOME . | Regimen . | P value (daunorubicin + AraC vs HD-AraC) (Fisher exact) . | Regimen . | P value (HMA vs AzaVen) . | ||
|---|---|---|---|---|---|---|
| Daunorubicin + AraC (N = 31) . | HD-AraC regimen (N = 50) . | |||||
| HMA (N = 36) . | AzaVen (N = 18) . | |||||
| Response after first induction (%) | ||||||
| CR | 7 (23) | 12 (24) | ||||
| CRi | 0 | 2 (4) | ||||
| cMPN | 11 (35) | 24 (48) | .15 | – | – | – |
| SD | 8 (26) | 7 (14) | ||||
| PD | 3 (10) | 0 | ||||
| Early death | 2 (6) | 5 (10) | ||||
| Overall response after first induction (%) | ||||||
| Response (CR/CRi/cMPN) | 18 (58) | 38 (76) | – | – | – | |
| Nonresponse (SD, PD, early death) | 13 (42) | 12 (24) | .14 | |||
| Second chemotherapy induction given (%) | ||||||
| Yes | 9 (29)∗ | 2 (4)† | .002 | – | – | – |
| No | 22 (71) | 48 (96) | ||||
| Best response (%) | ||||||
| CR | 9 (29) | 12 (24) | .38 | 1 (3) | 3 (17) | |
| CRi | 1 (3) | 2 (4) | 0 | 0 | ||
| cMPN | 13 (42) | 25 (50) | 11 (31) | 6 (33) | .14 | |
| SD | 3 (10) | 6 (12) | 16 (44) | 9 (50) | ||
| PD | 3 (10) | 0 | 5 (14) | 0 | ||
| Early death | 2 (6) | 5 (10) | 3 (8) | 0 | ||
| Overall best response (%) | ||||||
| Response (CR/CRi/cMPN) | 23 (74) | 39 (78) | .79 | 12 (33) | 9 (50) | .26 |
| Nonresponse (SD, PD, early death) | 8 (26) | 11 (22) | 24 (67) | 9 (50) | ||
| OUTCOME . | Regimen . | P value (daunorubicin + AraC vs HD-AraC) (Fisher exact) . | Regimen . | P value (HMA vs AzaVen) . | ||
|---|---|---|---|---|---|---|
| Daunorubicin + AraC (N = 31) . | HD-AraC regimen (N = 50) . | |||||
| HMA (N = 36) . | AzaVen (N = 18) . | |||||
| Response after first induction (%) | ||||||
| CR | 7 (23) | 12 (24) | ||||
| CRi | 0 | 2 (4) | ||||
| cMPN | 11 (35) | 24 (48) | .15 | – | – | – |
| SD | 8 (26) | 7 (14) | ||||
| PD | 3 (10) | 0 | ||||
| Early death | 2 (6) | 5 (10) | ||||
| Overall response after first induction (%) | ||||||
| Response (CR/CRi/cMPN) | 18 (58) | 38 (76) | – | – | – | |
| Nonresponse (SD, PD, early death) | 13 (42) | 12 (24) | .14 | |||
| Second chemotherapy induction given (%) | ||||||
| Yes | 9 (29)∗ | 2 (4)† | .002 | – | – | – |
| No | 22 (71) | 48 (96) | ||||
| Best response (%) | ||||||
| CR | 9 (29) | 12 (24) | .38 | 1 (3) | 3 (17) | |
| CRi | 1 (3) | 2 (4) | 0 | 0 | ||
| cMPN | 13 (42) | 25 (50) | 11 (31) | 6 (33) | .14 | |
| SD | 3 (10) | 6 (12) | 16 (44) | 9 (50) | ||
| PD | 3 (10) | 0 | 5 (14) | 0 | ||
| Early death | 2 (6) | 5 (10) | 3 (8) | 0 | ||
| Overall best response (%) | ||||||
| Response (CR/CRi/cMPN) | 23 (74) | 39 (78) | .79 | 12 (33) | 9 (50) | .26 |
| Nonresponse (SD, PD, early death) | 8 (26) | 11 (22) | 24 (67) | 9 (50) | ||
PD, progressive disease. Bold values are statistically significant.
Patients initially treated with 3+7 and achieving cMPN (n = 1), SD (n = 6), and PD (n = 2); 8 received HD-AraC–based regimen for reinduction; 1 unknown; responses were CR (n = 2), cMPN (n = 3), CRi (n = 1), SD (n = 1), PD (n = 2).
Patients initially treated with FLAG-IDA/NOVE-HiDAC and achieving SD (n = 2); both patients received alternate HD-AraC regimen achieving cMPN (n = 1) and CRi (n = 1).